Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis
Pediatric Allergy and Immunology · 2024
DOI: 10.1111/pai.14203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Koki Sasamoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Minami-ku Sagamihara, Japan. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Pyroglyphidae, Antigens, Dermatophagoides, Rhinitis, Allergic, Perennial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years.
Methods
Children aged 1–4 years with AR were divided into SLIT ( n = 22) and control ( n = 12) groups based on their guardians' preferences. The SLIT group received a daily dose of 10,000 JAU of HDM SLIT‐tablet for 12 months, whereas the control group received symptomatic treatment only.
Results
The baseline median age was 41 and 34 months in the SLIT and control groups, respectively, and the median AR symptom score was 4 for both groups. Compared with baseline, the AR symptom score had decreased significantly in the SLIT group after 12 months (score: 3, p = .002), whereas it tended to increase in the control group (score: 6, p = .08). Adverse reactions to SLIT were mild and occurred in eight patients (36%). In the SLIT group, Dermatophagoides ( D. ) farinae ‐specific IgE (sIgE) levels increased during the first 6 months and decreased to baseline levels at 12 months. In the control group, D. farinae ‐sIgE levels had increased significantly at 12 months compared to baseline ( p = .01). D. farinae‐ specific IgG 4 and HDM IgE‐blocking factor levels were significantly increased at 12 months compared to baseline in the SLIT group only ( p < .001). A lower wheezing frequency was seen in the SLIT group (0.3%) compared to the control group (0.7%).
Conclusion
This pilot study demonstrated the efficacy, safety, and immunomodulatory effects of HDM SLIT‐tablet in preschoolers with AR. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Minami-ku Sagamihara, Japan.
- Department of Pediatrics, Toho University Ohashi Medical Center, Meguro-ku, Japan.
- Torii Pharmaceutical Co., Ltd., Chuo-ku, Japan.
ORCID-Profile: Koki Sasamoto, Ken-Ichi Nagakura, Tomoyuki Asaumi, Naoko Fusayasu, Katsuyo Ohashi-Doi, Noriyuki Yanagida, Sakura Sato, Motohiro Ebisawa
Zitieren
APA
Sasamoto, K., Nagakura, K. I., Asaumi, T., Fusayasu, N., Ohashi-Doi, K., Yanagida, N., Sato, S., & Ebisawa, M. (2024). Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14203
Vancouver
Sasamoto K, Nagakura KI, Asaumi T, Fusayasu N, Ohashi-Doi K, Yanagida N, et al. Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14203
BibTeX
@article{Sasamoto2024,
author = {Sasamoto, Koki and Nagakura, Ken-Ichi and Asaumi, Tomoyuki and Fusayasu, Naoko and Ohashi-Doi, Katsuyo and Yanagida, Noriyuki and Sato, Sakura and Ebisawa, Motohiro},
title = {Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis},
journal = {Pediatric Allergy and Immunology},
year = {2024},
doi = {10.1111/pai.14203}
}
EUVIMED